• Explore /
  • Poster
  • / Exploratory analysis of biomarkers of response to durvalumab in advanced HER2-negative oesophago-gastric adenocarcinoma within a phase 2 clinical trial.

Exploratory analysis of biomarkers of response to durvalumab in advanced HER2-negative oesophago-gastric adenocarcinoma within a phase 2 clinical trial.

Abstract Poster

Authors

null

Hazel Lote

The Institute of Cancer Research and The Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom

Hazel Lote , Eleftheria Giota , Caroline Fong , Anderley Gordon , Ruwaida Begum , Laura Satchwell , Shannon Kidd , Susan Cromarty , Charlotte Victoria Fribbens , Naureen Starling , Sheela Rao , Ian Chau , David Cunningham , Luis Zapata

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Cancers of the Esophagus and Stomach and Other Gastrointestinal Cancers

Track

Esophageal and Gastric Cancer,Other GI Cancer

Sub Track

Translational Research

Clinical Trial Registration Number

NCT02678182

Citation

J Clin Oncol 42, 2024 (suppl 3; abstr 384)

DOI

10.1200/JCO.2024.42.3_suppl.384

Abstract #

384

Poster Bd #

J7

Abstract Disclosures

Similar Posters

First Author: Glenn J. Hanna

First Author: Tae-Yong Kim

First Author: Serigne N. Lo

First Author: David Tougeron